CatalystMarker
← board

GTBP

distress 7/10 · high distress / dilution risk
$0.34-2%today-85% from 52w high
gtbiopharma.com1 employeesFounded 1965San Francisco, CABiotechnology
Lead: relapsed or refractory CD33 expressing hematologic malignancies
Revenue
pre-revenue
Liquidity
$17M
Runway
1.3 yrs
Shares 1y
+914%

Price & events

-52.8% over 6M
$0.27$0.51$0.74Jan 26Apr 26Jul 2614.8Mdilution: EFFECT shelf_effective (2026-05-13)dilution: 424B3 offering (2026-05-13)dilution: S-1 shelf_registration (2026-04-30)dilution: 424B3 offering (2026-01-30)dilution: EFFECT shelf_effective (2026-01-30)financing: 8-K material_agreement (2026-04-07)
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-11.4%
1W
-31.1%
1M
-5.2%
3M
-52.2%
6M
-84.0%
1Y
-87.8%
2Y
-99.9%
5Y
-99.8%
All

Overview

Market Cap
$12.27M
Volume
31.03K
52 Week Range
$0.27 – $2.23
Total Shares
36.06M
Float Shares
33.47M
Short %
9.50%
% Held by Insiders
5.81%
% Held by Institutions
3.89%
RVOL
0.03x
Beta
0.84

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 36,062,904 · 4 offerings/1y · 0 PIPEs
  • 2026-05-13424B3offering
  • 2026-05-13EFFECTshelf_effective
  • 2026-04-30S-1shelf_registration
  • 2026-04-078-Kmaterial_agreement
  • 2026-01-30EFFECTshelf_effective
  • 2026-01-30424B3offering
  • 2026-01-21S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2024-12-02Roth MKMBuy

Competitors — relapsed or refractory CD33 expressing hematologic malignancies

  • none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.